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Introduction
The measurement of antigen-specific B cell numbers using 
Enzyme-Linked Immunosorbent Spot (ELISpot) assays has pro-
vided new insights into the biology of the immune response fol-
lowing immunization and has been used in many clinical vaccine 
trials.1-6 This method relies on the isolation of peripheral blood 
mononuclear cells (PBMCs) from blood specimens collected at 
study visits before and after a stimulus to the immune system 
such as an immunization. Although frequently used, the vari-
ability of the B cell ELISpot assay between different laboratories 
or operators or between fresh and frozen PBMC samples has not 
been formally studied. These parameters are important in order 
to combine data produced in different laboratories in multi-cen-
ter studies or at different time points.
Storage and cryopreservation of human lymphocytes
Cryopreservation allows lymphocytes to be stored long-term 
before being used in immunological assays. It involves cooling the 
sample before transferring it into liquid nitrogen for long-term 
storage. In this way, samples from multiple time points may be 
stored until they can be analyzed simultaneously, reducing varia-
tion arising from different assay runs. Frozen samples may also 
be transported to a single laboratory for analysis, reducing poten-
tial variation introduced by different operators and laboratory 
conditions. It is important that freezing, storage, and thawing 
does not have an excessive negative impact on assay performance. 
One parameter which can be affected by cryopreservation is cell 
viability. A median viable cell recovery of 50% following the 
thawing of frozen PBMCs was reported in one study,7 although 
there was no significant subsequent progressive reduction in the 
percentage of viable cells recovered after prolonged storage over 
the 12-y study period. A more recent study in which all samples 
were processed by a single experienced technician in the same 
laboratory, reported over 80% recovery of viable cells.8
The effects of cryopreservation on detection of memory B 
cells have not previously been studied. The effect of freezing of 
PBMCs on B cell responses has been investigated by Kyu et al. 
who studied the antibody-secreting cell (ASC) response to 3 
influenza antigens (H1, H3 and H7).9 No difference in H1 and 
H3-specific ASC frequencies was found when comparing fresh 
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The eLIspot assay is used in vaccine studies for the quantification of antigen-specific memory B cells (BMeM), and can 
be performed using cryopreserved samples. The effects of cryopreservation on BMeM detection and the consistency of 
cultured eLIspot assays when performed by different operators or laboratories are unknown. In this study, blood was 
taken from healthy volunteers, and a cultured eLIspot assay was used to count BMeM specific for 2 routine vaccine antigens 
(diphtheria and tetanus toxoid). Results were assessed for intra- and inter-operator variation, and the effects of cryo-
preservation. cryopreserved samples were shipped to a second laboratory in order to assess inter-laboratory variation. 
BMeM frequencies were very strongly correlated when comparing fresh and frozen samples processed by the same opera-
tor, and were also very strongly correlated when comparing 2 operators in the same laboratory. Results were slightly less 
consistent when samples were processed in different laboratories but correlation between the 2 measurements was 
still very strong. Although cell viability was reduced in some cryopreserved samples due to higher temperatures during 
transportation, BMeM could still be quantified. These results demonstrate the reproducibility of the eLIspot assay across 
operators and laboratories, and support the use of cryopreserved samples in future BMeM studies.
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and frozen samples, and detection of H7-specific ASCs was 
minimal but similar in both groups. The effect of cryopreserva-
tion on T cell responses has been more extensively studied, but 
results have been mixed. Although cryopreservation of PBMCs 
can alter cell surface markers,10-12 cytokine production,11,13 and 
cell proliferation,14 such discrepancies can be minimized when 
an optimized protocol is used.12,15-17 Preservation of cell function 
has been shown to be improved if PBMCs are frozen within 12 h 
of blood collection17 and temperature fluctuations are minimized 
during storage.18
Variability of the ELISpot assay
The B cell ELISpot assay was initially designed for the detec-
tion of spontaneously antibody-secreting cells,19 but has been fur-
ther developed to enable quantification of memory B cells (B
MEM
) 
by the inclusion of a stimulation step in which B
MEM
 differenti-
ate into detectable antibody-secreting cells.20 Although the basic 
principles remain unchanged, assay protocols are not standard-
ized between laboratories and are continually undergoing opti-
mization.21 Similarly protocols for ELISpot assays detecting T 
cell cytokine secretion vary,22 and studies of their reproducibility 
have shown substantial inter-laboratory variation.23-25 However, 
reproducible T cell ELISpot results can be achieved if 
assay and data analysis procedures are standardized across 
centers,26 suggesting that the compilation of results from 
different laboratories may be appropriate in the context of 
multi-center clinical trials.
The aim of this study was to compare the results of 
quantification of antigen-specific B
MEM
 using ELISpot 
when performed by different operators and in different 
laboratories using a standardized protocol and likewise 
to compare results using both fresh and frozen samples.
Materials and Methods
PBMC isolation and ELISpot
The cultured ELISpot assay to detect antigen-spe-
cific B
MEM
 was performed as previously described.27,28 
PBMCs were first isolated from whole blood using 
lymphoprep™ (Axis-Shield Diagnostics) density gra-
dient centrifugation. After a wash step, PBMCs were 
cultured at a concentration of 2 × 105 cells/well in a 
mixture of SAC (S. aureus Cowan strain, 1:5000, 
Calbiochem), CpG oligodeoxynucleotide 2006 (1.8 µg/mL, 
Source Bioscience) and pokeweed mitogen (PWM, 83 ng/
mL, Sigma) for 6 d at 37 °C, 5% CO
2
, and 95% humidity. 
Cells were then harvested, washed, and seeded at 2 × 105 via-
ble cells per well onto a 96-well plate with PVDF-membranes 
(Millipore) pre-coated with diphtheria or tetanus toxoid. Plates 
also included phosphate buffered saline (PBS) wells and poly-
valent goat anti-human Ig (10 μg/mL) wells as negative and 
positive controls respectively. Cell viability was assessed using 
the trypan blue dye exclusion test.29 In this test, only cells with 
an intact cell membrane exclude the dye, therefore viable cells 
remain unstained. Following overnight incubation, plates were 
washed before incubating the wells with a goat anti-human 
IgG conjugated to alkaline phosphatase (Calbiochem) to detect 
bound antibody. The antibody was visualized using the alkaline 
phosphatase substrate kit (Bio-Rad) and the reaction stopped 
with distilled water. Plates were then dried overnight in a dry-
ing-oven before being read using an automated ELISpot reader 
(AID ELR03, AID Diagnostika).
Cryopreservation of PBMCs
Following PBMC separation, cells were re-suspended (5 × 106 
cells/mL) in a cell freezing mix (Recovery™, Invitrogen, UK). 
One mL aliquots were placed into a freezing container ‘Mr Frosty’ 
(Nalgene®, VWR International, UK, pre-chilled at -20 °C), and 
held overnight at −80 °C before being transferred into liquid 
nitrogen for long-term storage. For thawing, vials were immersed 
in a 37 °C water bath and the PBMC solution transferred into 
10 mL of pre-warmed medium (‘complete medium’), containing 
RPMI-1640 (Hepes modification), 10% newborn bovine serum, 
1% Penicillin-Streptomycin, 1% L-Glutamine (all from Sigma-
Aldrich), 1% MEM Non-Essential Amino Acids, 1% MEM 
Sodium Pyruvate 100 mM, and 0.1% 2-Mercaptoethanol 1000× 
(all from Invitrogen). Following a wash step, the cells were pro-
cessed further as described above.
Figure  1. study design used to evaluate BMeM eLIspot variability. OP, 
operator.
Figure 2. Number of viable PBMcs (A) following thawing of the samples and (B) 
after 6 d in culture. significant differences in the PBMc counts were found both 
before and after culturing the cells between the frozen samples processed by 
operator 1 at site 1 and the frozen samples that were processed by operator 3, 
which were shipped to site 2. P values are calculated by two-tailed paired t test 
and horizontal bars indicate medians. Op, operator.
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Study design
A prospective study was conducted across 2 sites. Twelve 
healthy volunteers each donated 40 mL of venous blood each 
divided into 2 aliquots anticoagulated with 350 μL preserva-
tive-free heparin, and PBMCs were isolated within 2 h at site 1. 
Samples were divided into 4 parts: 2 parts were processed imme-
diately for culture and ELISpot, and 2 parts were cryopreserved 
for 6 mo. One of the cryopreserved samples was shipped to site 
2, and the other was processed fully at site 1. This study design 
(Fig. 1) allowed comparison between operators, between fresh 
and cryopreserved samples and between laboratories. Duplicate 
samples processed by each operator were assessed for intra-oper-
ator variability. During the 2 d transit period to site 2, cryopre-
served samples were kept on dry ice, and were transferred to 
storage at −80 °C on arrival where they were kept for 1 wk 
before processing. Following thawing, cell viability was 
assessed before performing the ELISpot assay. ELISpot 
assays were performed using plates pre-coated with diph-
theria and tetanus toxoids at a concentration of 10 and 
5 μg/mL, respectively, both included among routinely 
administered vaccines.
Blood was taken from laboratory personnel at site 1 in 
agreement with Oxford University Occupational Health 
Service Policy document 1/03 for taking blood samples 
from colleagues or students for research (https://www.
admin.ox.ac.uk/uohs/policies-guidance/blood/). Written 
informed consent was obtained from all study partici-
pants and samples were subsequently anonymized so that 
all operators were blinded to the study participant the 
samples came from during processing of the samples, and 
also when plates were read and counted.
Data analysis
All ELISpot plates were read and counted automati-
cally using pre-defined settings at study site 1 and spot 
numbers were manually corrected for the presence of arti-
facts identified as spots by the machine. If artifacts had 
been included in the automatic spot count, this number 
was subtracted from the total spot count from that well. 
Antigen-specific spot counts were calculated as the mean 
of 4 wells minus the mean spot count from PBS control 
wells. Samples with a low spot count in IgG control wells 
were excluded. Spot counts were multiplied by 5 to obtain 
B
MEM
 frequencies per million cultured PBMCs. All analyses were 
performed with these final frequencies, i.e., spots per million cul-
tured PBMCs.
Correlation between samples was assessed using the Pearson 
correlation coefficient and correlation was graded as low (r-values 
between 0.2–0.39), moderate (0.4–0.59), strong (0.6–0.79), and 
very strong (≥0.8). Agreement between B
MEM
 numbers obtained 
from duplicates of the same participants’ samples was assessed 
by generating Bland-Altman plots for each antigen and each 
operator. Overall, we defined assay reliability as acceptable for 
correlation coefficients ≥0.8. Statistical analysis and plots were 
performed using R30 and the ggplot2 package for R.31
Results
Numbers of viable PBMC obtained after thawing of frozen 
samples were significantly lower in samples which were kept on 
dry ice for transport to the other laboratory, both before and after 
culture (Fig. 2 and Table 1). However, when adjusted for num-
bers of viable cells that were put into culture, post-culture viable 
cell counts were not different between the 2 groups (data not 
shown).
A subset of automatically counted plates was corrected for 
artifacts independently by 2 operators who were blinded to the 
samples. A very strong correlation (r ≥ 0.97, P < 0.0001) between 
the 2 spot counts was found when numbers of spots for each 
Table 1. summary of PBMc counts following thawing and after the 6 d 
culture as determined by the different operators
Viable PBMC 
after thawing
(million cells)
Viable PBMC after 
6 d culture
(million cells)
Fresh (Op. 1) 3.8 (5.0–7.0)
Fresh (Op. 2) 3.6 (4.9–6.1)
Frozen (Op. 
1)
4.7 (5.5–6.7) 3.8 (4.7–5.7)
Frozen (Op. 
3)
2.4 (3.1–3.8) 2.3 (3.0–3.6)
shown are median values with interquartile ranges (IQR) in brackets. Op, 
operator.
Figure 3. scatterplot matrix of diphtheria toxoid-specific Asc/106 cultured PBMc 
using (A) fresh samples operator 1 vs. operator 2, (B) fresh operator 2 (Oxford) vs. 
frozen operator 3 (Bristol), (C) fresh vs. frozen samples operator 1, and (D) frozen 
samples operator 1 (Oxford) vs. operator 3 (Bristol).
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sample were compared. Subsequently, analysis of all plates was 
performed using spot counts from operator 1.
When comparing diphtheria and tetanus toxoid-specific B
MEM
 
between 2 independent operators within the same laboratory 
using fresh PBMC samples (operator 1 fresh vs. operator 2 fresh), 
correlation was very strong (Figs. 3A and 4A).
Comparison of fresh vs. frozen samples also showed very strong 
correlation for both diphtheria and tetanus toxoid-specific B
MEM
 
frequencies when processed by the same operator (Figs. 3C and 
4C). Inter-laboratory correlation, i.e., samples being processed by 
2 different operators in 2 different laboratories (operator 1 frozen 
vs. operator 3 frozen), was slightly lower but still significant when 
comparing diphtheria and tetanus toxoid-specific B
MEM
 frequen-
cies (Figs. 3D and 4D). Not unexpectedly, the lowest correlation 
was measured for both diphtheria and tetanus toxoid-specific 
B
MEM
 when samples were processed by different operators in dif-
ferent laboratories with one operator working with fresh and the 
other operator working with frozen samples (Figs. 3B and 4B).
The correlation coefficients for each of the comparisons 
discussed is summarized in Figure S1, which shows that each 
additional change during processing was associated with a small 
reduction in the strength of correlation.
The agreements between the duplicate samples processed by 
each operator (intra-operator agreement) are shown in Figures 5 
and 6, for fresh and frozen samples respectively. For fresh and 
frozen samples, systematic bias was equally low (0–11 spots/mil-
lion cultured PBMCs) in both groups of samples compared with 
the mean of duplicate samples (continuous lines in Figs. 5 and 
6). In general, the 95% limits of agreement were wider in frozen 
compared with fresh samples and for tetanus-specific compared 
with diphtheria-specific ASC frequencies (dashed lines in Figs. 5 
and 6). For higher average values, variability increased as sug-
gested by larger scatter around the bias line, which was especially 
true for tetanus-specific ASC frequencies.
Discussion
In this study, an ELISpot assay measuring numbers of B
MEM
 
was assessed for intra and inter-operator variability as well as inter-
laboratory performance and the effect of freezing of PBMCs. We 
found that intra-operator agreement of sample replicates was best 
for fresh samples with somewhat greater variability between rep-
licates for higher average spot counts. The limits of agreement 
were slightly wider for frozen samples but comparable between 
laboratories (Figs. 5 and 6).
B
MEM
 frequencies were very strongly correlated when 2 differ-
ent operators within the same laboratory processed samples. This 
Figure 4. scatterplot matrix of tetanus toxoid-specific Asc/106 cultured PBMc using (A) fresh samples operator 1 vs. operator 2, (B) fresh operator 2 
[Oxford] vs. frozen operator 3 (Bristol), (C) fresh vs. frozen samples operator 1, and (D) frozen samples operator 1 (Oxford) vs. operator 3 (Bristol).
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is an encouraging finding, as there are a number of stages in the 
ELISpot assay where variability may be introduced, particularly 
when different operators are processing samples. The method 
used to count B
MEM
 when analyzing plates may also introduce 
variability,32 therefore standardization of equipment and param-
eters for plate analysis are important. In this study, counting of 
spots in a semi-automated manner using pre-defined plate read-
ing settings followed by manual correction for artifacts, resulted 
in a very strong correlation when assessed by 2 different operators.
B
MEM
 counts from fresh and frozen samples were also very 
strongly correlated, demonstrating that cryopreservation does 
not have a negative impact on the detection of B
MEM
 in the 
cultured ELISpot, consistent with studies demonstrating reli-
able ASC and T cell ELISpot results when using cryopreserved 
samples.9,15-17 Although, as expected, fluctuating temperatures 
experienced by the cells in transit resulted in a lower yield of 
viable cells, antigen-specific B
MEM
 frequencies could still be reli-
ably measured. Compared with T cells, which have been shown 
to display reduced antigen-specific responses after experiencing 
fluctuating storage temperatures,18 B
MEM
 may be more resilient 
under these conditions. Although previous studies have shown 
that low cell viability following cryopreservation can compro-
mise lymphocyte proliferation in response to mitogens including 
PWM,33 the present study shows that after allowing for lower 
viable cell numbers following storage and shipment, freezing of 
PBMC did not affect the numbers of viable PBMCs that were 
harvested after a 6-d culture compared with fresh samples. This 
suggests that in this case, the remaining viable antigen-specific B 
cells responded to the polyclonal stimulators (PWM, CpG, and 
SAC) in the culture medium to the same degree as the fresh cells, 
and that these cells were not more susceptible to lower storage 
temperatures compared with other B cell subsets. Nevertheless, 
lower cell viability after shipping should be taken into account 
when planning the transport of samples between centers. Care 
should be taken to minimize the time cells are exposed to higher 
storage temperatures in order to maintain cell viability as much 
as possible.
As demonstrated in Figure S1, variability increases as addi-
tional processing variables are introduced e.g., when one sample 
is fresh and the other is frozen, or when samples are processed 
in different laboratories. Although correlation was lower when 
samples were processed in different laboratories, inter-labora-
tory variability was still relatively low and within the range of 
the variability that was found when 2 different operators within 
the same laboratory processed fresh samples, suggested by simi-
lar correlation coefficients between the 2 pairs (Figs. 3 and 4). 
Figure 5. Bland-Altman plots of intra-operator variability on fresh samples showing the difference between replicates processed by the same operator 
against the mean of 2 measurements. Bias (mean difference, continuous line) and 95% limits of agreement (dashed lines) are shown. (A) Operator 1, 
diphtheria toxoid; (B) Operator 1, tetanus toxoid; (c) Operator 2, diphtheria toxoid; (D) Operator 2, tetanus toxoid.
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Reproducibility of the ELISpot assay between laboratories is 
important in order to combine data in the context of multi-center 
studies. We, along with investigators studying the reproducibility 
of T cell ELISpots,26 have demonstrated that low inter-laboratory 
variability is achievable when using a standardized protocol.
Conclusion
In this study we found that the cultured B cell ELISpot is a 
robust and reproducible assay that can be performed on fresh or 
frozen samples and in different laboratories. Specific caution is 
advised when shipment of frozen samples to a different labora-
tory is considered, although antigen-specific B
MEM
 frequencies 
can still be reliably measured even with a lower number of viable 
cells resulting from fluctuating temperatures during shipment 
and storage.
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Figure  6. Bland-Altman plots of intra-operator variability on frozen 
samples showing the difference between replicates processed by the 
same operator against the mean of 2 measurements. Bias (mean differ-
ence, continuous line) and 95% limits of agreement (dashed lines) are 
shown. (A) Operator 1, diphtheria toxoid; (B) Operator 1, tetanus toxoid; 
(C) Operator 3, diphtheria toxoid; (D) Operator 3, tetanus toxoid.
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